AI Article Synopsis

  • PPARG (peroxisome proliferator-activated receptor gamma) is involved in lipid and glucose regulation and has been studied for its potential link to breast cancer (BC), but results have been inconsistent.
  • A meta-analysis of nine studies with nearly 3,931 BC cases and 5,382 controls found no overall significant association between the PPARG rs1801282 C>G variant and BC risk, but significant protective associations were noted in Caucasian women and post-menopausal women.
  • The findings suggest that the PPARG rs1801282 C>G variant may lower BC risk in specific groups, but no significant link was found for another variant, PPARG rs3856806 C>T

Article Abstract

Background: Peroxisome proliferator-activated receptor gamma (PPARG), a nuclear hormone receptor, plays a critical role in the lipid and glucose homeostasis, adipocyte differentiation, as well as intracellular insulin-signaling events. Several studies have been conducted to explore the associations of PPARG polymorphisms with breast cancer (BC), yet the findings are inconsistent.

Methods: Databases of Pubmed and Embase were searched until October 5, 2014. The association between PPARG polymorphisms and BC risk was determined by crude odds ratios (ORs) with their 95% confidence intervals (CIs).

Results: Finally, there are nine publications involving 3,931 BC cases and 5,382 controls included in this meta-analysis. No significant association was observed between PPARG rs1801282 C>G variants and overall BC risk in all genetic comparison models. However, in a subgroup analysis by ethnicity, significant association was observed between PPARG rs1801282 C>G variants and decreased BC risk in three genetic models: GG+CG vs. CC (OR, 0.83; 95% CI, 0.71-0.96; P = 0.011), CG vs. CC (OR, 0.82; 95% CI, 0.71-0.96; P = 0.011) and G vs. C (OR, 0.85; 95% CI, 0.75-0.97; P = 0.016) in Caucasians and in a subgroup analysis by menopausal status, significantly decreased BC risk was also found in two genetic models: GG+CG vs. CC (OR, 0.79; 95% CI, 0.67-0.95; P = 0.011) and CG vs. CC (OR, 0.77; 95% CI, 0.64-0.92; P = 0.005) in post-menopause subgroup. For PPARG rs3856806 C>T, we found no significant association between PPARG rs3856806 C>T polymorphism and breast cancer.

Conclusions: In summary, despite some limitations, the results suggest that PPARG rs1801282 C>G polymorphism may be a protective factor for BC in Caucasians and in post-menopause women.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612818PMC

Publication Analysis

Top Keywords

pparg polymorphisms
12
pparg rs1801282
12
rs1801282 c>g
12
pparg
9
peroxisome proliferator-activated
8
proliferator-activated receptor
8
receptor gamma
8
gamma pparg
8
polymorphisms breast
8
breast cancer
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!